OHR Pharmaceutical I

Delayed Nasdaq - 07/16 10:00:00 pm
4.64USD
+1.98%

OHR PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Ohr Pharmaceutical, Inc. - OHRP

Envoyer par e-mail
02/11/2019 | 11:47 pm

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Ohr Pharmaceutical, Inc. (“Ohr”) (NasdaqCM: OHRP) with NeuBase Therapeutics, Inc. (“NeuBase”) in a stock-for-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-ohrp/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Business Wire 2019
Envoyer par e-mail